Načítá se...
Azacitidine-induced acute lung injury in a patient with therapy-related myelodysplastic syndrome
Azacitidine is a first-in-class demethylating agent, and it is widely used globally as a first-line treatment for higher-risk myelodysplastic syndrome (MDS). Here, we report the case of a patient with MDS who suffered from a rare adverse event, an acute lung injury (ALI), which was suspected to have...
Uloženo v:
| Vydáno v: | J Int Med Res |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5536648/ https://ncbi.nlm.nih.gov/pubmed/28415946 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060517698331 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|